Intercell, Iomai merger OK'd by Committee on Foreign Investment

By Lisa Kerner

Charlotte, N.C., June 18 - The Committee on Foreign Investment in the United States determined there were no unresolved national security concerns in the proposed acquisition of Iomai Corp. by Intercell AG, it was reported in a form 8-K filed with the Securities and Exchange Commission.

On May 12, Intercell announced it would acquire Iomai for $6.60 a share, or a total of $189 million.

The Federal Trade Commission has granted early termination of the Hart-Scott-Rodino waiting period in the proposed merger, a prior form 8-K filing stated.

The transaction, expected to close in the third quarter, requires the approval of Iomai stockholders.

Intercell is a biotechnology company based in Vienna.

Iomai is a Gaithersburg, Md., developer of vaccines and immune system stimulants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.